Skip to main content
BIVI logo

BIVI · Biovie Inc. · Investor Relations

Track BIVI — free
$1.24 -0.13 (-9.49%) At close · Oct 20
Market Cap
$9.39M
Shares
7.54M
Volume · Oct 20 279.49K Avg daily vol (3M) 4.52M

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date Headline
2026-10-20 BioVie Presents Data on Bezisterim in Parkinson’s Disease at the 2026 American Neurological Association Annual Meeting
2026-10-19 BioVie Presents Data on Bezisterim in Long COVID at the 2026 American Neurological Association Annual Meeting
2026-10-14 BioVie to Present New Bezisterim Findings in Parkinson’s Disease and Long COVID at the 2026 American Neurological Association Annual Meeting
2026-09-15 BioVie Announces Topline Results from Phase 2 ADDRESS‑LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
2026-09-14 BioVie to Host Conference Call to Discuss Topline Data from Phase 2 ADDRESS-LC Trial and the Potential of Bezisterim in Long Covid
2026-09-08 BioVie Announces Update to Parkinson’s Phase 3 Development Program
2026-08-31 BioVie Announces Completion of Treatment Phase of ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
2026-08-06 BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson’s Disease
2026-05-27 Join BioVie’s Exclusive Live Investor Webinar and Q and A Session on June 2
2026-05-26 BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
2026-05-18 BioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early-Stage Parkinson’s Disease
2026-04-27 BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026
2026-04-14 BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual Meeting
2026-03-12 BioVie Announces Abstract Accepted for Presentation at AD/PD 2026
2026-02-23 Join Biovie’s Exclusive Live Investor Webinar and Q&A Session on March 4
2026-02-12 BioVie Announces Abstracts Accepted for Presentation at the 2026 American College of Psychiatrists Annual Meeting
2026-01-08 BioVie Completes Enrollment in Phase 2 SUNRISE-PD Trial in Early Parkinson’s Disease
2025-11-19 Join Biovie’s Exclusive Live Investor Webinar and Q&A Session on December 9

Past events

Source: https://investors.bioviepharma.com/overview/default.aspx

Key facts CIK 1580149 CUSIP 09074F504 Visit website Investor relations